chufangao/CTO huggingface dataset:
Clinical trial NCT04582318: A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
Official title: A Randomized, Double Blind, Placebo Controlled, Combined Phase 1/2 Single Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of NGM621 in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Subjects With Confirmed SARS-CoV-2 Infection
Sponsor: NGM Biopharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to the rapidly changing therapeutic landscape in the COVID-19 space and an assessment of unmet medical need, Part 2 of the study was cancelled (per protocol Section 4.3). Meanwhile, Part 1 of the study was completed.
Enrollment: 16.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-11-09
Primary completion date: 2021-02-18
Completion date: 2021-03-11
Plan to share individual participant data: UNDECIDED
IPD sharing description: This is a proof-of-concept study assessing the safety, tolerability, PK, and efficacy of systemic use of NGM621 versus placebo in both healthy subjects and subjects confirmed with SARS-CoV-2 infection. We will continue to evaluate whether IPD will be shared with other researchers.
Clinical trial NCT02555111: Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Official title: Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Acronym: RIPORT
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 112.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03389438: Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Official title: A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin
Sponsor: Beijing Huanxing Cancer Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Shortage of funds.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-26
Primary completion date: 2021-02-26
Completion date: 2021-10-31
Plan to share individual participant data: NO
Clinical trial NCT01938547: Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Official title: Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery
Acronym: PIONEER
Sponsor: Chiesi Farmaceutici S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-03-31
Primary completion date: 2024-02-20
Completion date: 2024-02-20
Plan to share individual participant data: NO
Clinical trial NCT03920657: Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Official title: Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: enrollment failed
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-04
Primary completion date: 2020-10-06
Completion date: 2022-04-22
Plan to share individual participant data: NO
Clinical trial NCT04285749: Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Official title: Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: PI moving to new institution prior to study activation
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-06
Primary completion date: 2021-04-01
Completion date: 2021-04-01
Plan to share individual participant data: NO
IPD sharing description: This study is a pilot study to help assess the power needed for a larger study and to determine biologic activity. If a larger study is conducted, data will be shared.
Clinical trial NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
Official title: A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil Alone or With Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment (DIVERT) (ALE10)
Acronym: DIVERT
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was closed due to slow enrollment.
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-10-28
Primary completion date: 2024-04-20
Completion date: 2024-04-20
Plan to share individual participant data: YES
IPD sharing description: The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD time frame: On average, within 24 months after database lock for the trial.
IPD access criteria: Open access.
Clinical trial NCT03496623: A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Acronym: PERFECT
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 188.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-08
Primary completion date: 2022-10-13
Completion date: 2022-10-13
Baseline population: Full Analysis Set included all participants who were randomized and received at least one dose of study drug.
Limitations and caveats: Per sponsor decision, the study was terminated early. Data were not collected for the secondary outcome measures due to study termination and lack of appropriate sample size.
Plan to share individual participant data: NO
Clinical trial NCT03257722: Pembrolizumab + Idelalisib for Lung Cancer Study
Official title: A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor
Acronym: PIL
Sponsor: Augusta University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to poor accrual.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-26
Primary completion date: 2020-08-15
Completion date: 2021-08-25
Baseline population: No patients were enrolled in Phase 2.
Plan to share individual participant data: NO
Clinical trial NCT02597660: A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy
Official title: A Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy
Sponsor: Hospital for Special Surgery, New York (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI decided not to enroll
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Clinical trial NCT05242432: A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Efficacy, Safety, Reactogenicity, and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Japanese Adults Aged 60 Years and Older, and Safety, Reactogenicity, and Immunogenicity of the Vaccine in Japanese Adults Aged 20 to 59 Years at High-risk of RSV Disease
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Terminated (Janssen made the strategic decision to discontinue the RSV3007 study. This decision is not based on any safety concerns.)
Enrollment: 2192.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-04-01
Primary completion date: 2023-03-20
Completion date: 2023-03-20
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02587962: Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Official title: A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors
Sponsor: Medivir (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Based on a futility analysis, the data monitoring committee recommended to stop enrollment.
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-04
Primary completion date: 2020-02-17
Completion date: 2020-02-17
Limitations and caveats: The dose escalation (Phase 1) part was analyzed per the protocol. Based on data from the interim analysis of the colorectal cancer cohort (dose expansion \[Phase 2\] part), the study was closed early due to futility on recommendation by the data monitoring committee (DMC).
Plan to share individual participant data: NO
Clinical trial NCT03552692: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Official title: A Phase II, Open Label, Multicenter Trial of Venetoclax (ABT-199/GDC-0199) as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal T-cell Lymphomas of T-follicular Helper Origin (TFH)
Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: efficacy lower than expected
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-25
Primary completion date: 2020-03-04
Completion date: 2023-02-17
Plan to share individual participant data: NO
Clinical trial NCT04476329: Optimization for Regorafenib in HCC
Official title: A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib
Acronym: ReDos HCC
Sponsor: SC Liver Research Consortium, LLC (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-21
Primary completion date: 2021-10-13
Completion date: 2021-12-10
Plan to share individual participant data: NO
IPD sharing description: Only aggregated data will be available for review, analysis and reporting.
Clinical trial NCT05099822: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of CC-97489 in Healthy Adult Subjects
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives changed.
Enrollment: 84.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-13
Primary completion date: 2022-07-11
Completion date: 2022-07-11
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT03447262: A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
Official title: A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: At Sponsor's Discretion
Enrollment: 484.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-13
Primary completion date: 2020-09-09
Completion date: 2020-09-09
Clinical trial NCT03226522: Addressing Dementia Via Agitation-Centered Evaluation
Official title: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Acronym: ADVANCE
Sponsor: Axsome Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 366.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-07-13
Primary completion date: 2020-04-17
Completion date: 2020-04-17
Plan to share individual participant data: NO
Clinical trial NCT05097326: Mifepristone for Labor Induction
Official title: Mifepristone as an Adjunct to Transcervical Balloon for Labor Induction (MiLI): A Randomized Clinical Trial
Acronym: MiLI
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-27
Primary completion date: 2023-04-29
Completion date: 2023-04-29
Plan to share individual participant data: NO
Clinical trial NCT05039190: Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Seamless and Group Sequential Phase 2/3 Study to Evaluate the Efficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Acronym: MG
Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-25
Primary completion date: 2023-01-14
Completion date: 2023-01-14
Clinical trial NCT02867280: Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Official title: A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Midterm analysis showed negative results.
Enrollment: 154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-01
Primary completion date: 2019-08-31
Completion date: 2020-01-31
Plan to share individual participant data: NO
Clinical trial NCT02924883: A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
Official title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Acronym: KATE2
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 202.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-26
Primary completion date: 2017-12-11
Completion date: 2020-02-06
Clinical trial NCT05205759: Non-inferiority Trial on Monoclonal Antibodies in COVID-19
Official title: Adaptive, Randomized, Non-inferiority Trial to Evaluate the Efficacy of Monoclonal Antibodies in Outpatients With Mild or Moderate COVID-19
Acronym: MANTICO
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Stop for futility after the onset of the omicron wave
Enrollment: 319.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-09
Primary completion date: 2022-02-05
Completion date: 2022-04-05
Clinical trial NCT03018249: Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Official title: A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-11
Primary completion date: 2018-04-18
Completion date: 2021-03-12
Baseline population: Eligible patients
Clinical trial NCT05001022: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
Official title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-020572 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Multiple Doses in Subjects With Chronic Hepatitis B (Part 2)
Sponsor: Aligos Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: ALT flares suggestive of drug induced liver injury
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-25
Primary completion date: 2022-07-18
Completion date: 2022-07-18
Clinical trial NCT02995005: Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus
Official title: Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy
Sponsor: Johns Hopkins Bloomberg School of Public Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 98.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-24
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: YES
IPD sharing description: The investigators are currently developing an individual participant data (IPD) sharing plan.
IPD time frame: Data will become available 6 months after publication of the main report.
IPD access criteria: Permission by corresponding author
Clinical trial NCT03251911: VX-770 for the Treatment of Chronic Bronchitis
Official title: An Open Label Study to Investigate the Role of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis With CFTR Dysfunction
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: no participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-01
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: NO
Clinical trial NCT04680962: MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Official title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20, EU-approved MabThera® and US-licensed Rituxan® in Patients With Moderate-to-Severe Rheumatoid Arthritis
Acronym: MABRIDGE
Sponsor: Mabion SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study closed for business reasons before patient recruitment was initiated.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-08-03
Primary completion date: 2023-08-03
Completion date: 2023-08-03
Plan to share individual participant data: NO
Clinical trial NCT04088760: TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Official title: Safety and Efficacy of TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders in Children and Adolescent/Young Adult Patients
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Post-transplant cyclophosphamide and abatacept can be used as standard-of-care approaches to GVHD prevention in the HLA mismatched donor-recipient setting and are simpler to use since study enrollment is not required.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-16
Primary completion date: 2021-05-14
Completion date: 2021-09-03
Plan to share individual participant data: NO
Clinical trial NCT03661047: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Official title: OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Acronym: OMICC
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study will be closed due to zero enrollment in over 2 years.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-30
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Clinical trial NCT04287543: Melatonin on Clock Genes in Parkinson's Disease
Official title: Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease
Sponsor: Instituto Mexicano del Seguro Social (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Due to the COVID-19 pandemic, we were unable to begin the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-31
Primary completion date: 2022-07-31
Completion date: 2022-08-31
Plan to share individual participant data: YES
IPD sharing description: It is planned to inform the patient individually about their results; if the results are favorable it will be considered to apply them to the Clinical of Movement Disorders patients. All data will be published in an article.
Clinical trial NCT03122639: Endothelial Function in Obstructive Sleep Apnea
Official title: Vascular Endothelial Activation in Obstructive Sleep Apnea
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-01
Primary completion date: 2020-01-30
Completion date: 2021-05-07
Plan to share individual participant data: NO